Development of a Multiplex Assay for Prediction of Immunotherapy Response in Metastatic Melanoma Patients
Melanoma is the most aggressive among all skin cancers and is responsible for high mortality rate. Combined immunotherapies have demonstrated a greater efficacy to boost the immune system of melanoma patients. However, the clinical decision on which combination to be used and which patients will benefit the most from it, remains a challenge. Understanding the immune context of patients’ tumor and the identification of reliable biomarker redouts will assist clinicians in their decision. We developed a multiplex immunohistochemistry assay to profile the tumor microenvironment of metastatic melanoma patients who responded or not to combined immunotherapy. We used LabSat®, an automated stainer based on Lunaphore’s microfluidic technology, to analyze the expression of PD-L1, CD8 and LAG-3. Our results provide first-time evidence of a different expression pattern of these markers between responder and non-responder melanoma patients.
Wednesday, May 18, 2022 · 3:00 p.m.
Bern (GMT +2:00)
Dr. Paolo Ascierto
Director of the Unit of Melanoma, National Tumor Institute G. Pascale
Dr. Gabriele Madonna
Health Researcher, National Tumor Institute G. Pascale